Christina Schröder1,2, Rita Engenhart-Cabillic3, Hilke Vorwerk3, Michael Schmidt4, Winfried Huhnt4, Eyck Blank4, Dietrich Sidow4, André Buchali4. 1. Clinic for Radiotherapy and Radiation Oncology, University Clinic Giessen and Marburg, Marburg, Germany. christina.schroeder@med.uni-giessen.de. 2. Clinic for Radiotherapy and Radiation Oncology, Ruppiner Kliniken GmbH, Neuruppin, Germany. christina.schroeder@med.uni-giessen.de. 3. Clinic for Radiotherapy and Radiation Oncology, University Clinic Giessen and Marburg, Marburg, Germany. 4. Clinic for Radiotherapy and Radiation Oncology, Ruppiner Kliniken GmbH, Neuruppin, Germany.
Abstract
PURPOSE: Using prospectively collected patient-related, dose-related, and pulmonary function test (PFT) data before radiotherapy (RT) and at several follow-up visits after RT, the time course of PFT changes after high-dose radio(chemo)therapy and influencing factors were analyzed. MATERIALS AND METHODS: From April 2012 to October 2015, 81 patients with non-small-cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC), or esophageal carcinoma where treated with high-dose radio(chemo)therapy. PFT data were collected before treatment and 6 weeks, 12 weeks, and 6 months after RT. The influence of patient- and treatment-related factors on PFT was analyzed. RESULTS: Mean forced expiratory volume in 1 s (FEV1) constantly declined during follow-up (p = 0.001). In total, 68% of patients had a reduced FEV1 at 6 months. Mean vital capacity (VC) didn't change during follow-up (p > 0.05). Mean total lung capacity (TLC) showed a constant decline after RT (p = 0.026). At 6 months, 60% of patients showed a decline in VC and 73% in TLC. The mean diffusion capacity for carbon monoxide (DLCO) declined at 6 and 12 weeks, but recovered slightly at 6 months (p < 0.0005). At 6 months, 86% of patients had a reduced DLCO. After treatment, the partial pressure of CO2 in the blood (pCO2) was increased and pO2 was decreased (p > 0.05). Only the pretreatment PFT classification had a significant influence on the post-RT FEV1. CONCLUSION: DLCO seems to be the most reliable indicator for lung tissue damage after thoracic RT. Ventilation parameters appear to be less reliable. Concerning patient- or treatment-related factors, no reliable conclusion can be drawn regarding which factors may be relevant.
PURPOSE: Using prospectively collected patient-related, dose-related, and pulmonary function test (PFT) data before radiotherapy (RT) and at several follow-up visits after RT, the time course of PFT changes after high-dose radio(chemo)therapy and influencing factors were analyzed. MATERIALS AND METHODS: From April 2012 to October 2015, 81 patients with non-small-cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC), or esophageal carcinoma where treated with high-dose radio(chemo)therapy. PFT data were collected before treatment and 6 weeks, 12 weeks, and 6 months after RT. The influence of patient- and treatment-related factors on PFT was analyzed. RESULTS: Mean forced expiratory volume in 1 s (FEV1) constantly declined during follow-up (p = 0.001). In total, 68% of patients had a reduced FEV1 at 6 months. Mean vital capacity (VC) didn't change during follow-up (p > 0.05). Mean total lung capacity (TLC) showed a constant decline after RT (p = 0.026). At 6 months, 60% of patients showed a decline in VC and 73% in TLC. The mean diffusion capacity for carbon monoxide (DLCO) declined at 6 and 12 weeks, but recovered slightly at 6 months (p < 0.0005). At 6 months, 86% of patients had a reduced DLCO. After treatment, the partial pressure of CO2 in the blood (pCO2) was increased and pO2 was decreased (p > 0.05). Only the pretreatment PFT classification had a significant influence on the post-RT FEV1. CONCLUSION: DLCO seems to be the most reliable indicator for lung tissue damage after thoracic RT. Ventilation parameters appear to be less reliable. Concerning patient- or treatment-related factors, no reliable conclusion can be drawn regarding which factors may be relevant.
Authors: Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: Jose L Lopez Guerra; Daniel R Gomez; Yan Zhuang; Lawrence B Levy; George Eapen; Hongmei Liu; Radhe Mohan; Ritsuko Komaki; James D Cox; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-13 Impact factor: 7.038
Authors: J C Theuws; Y Seppenwoolde; S L Kwa; L J Boersma; E M Damen; P Baas; S H Muller; J V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-15 Impact factor: 7.038
Authors: Matthias Guckenberger; Rainer J Klement; Larry L Kestin; Andrew J Hope; Jose Belderbos; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Inga S Grills Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-12 Impact factor: 7.038
Authors: Ramesh Gopal; George Starkschall; Susan L Tucker; James D Cox; Zhongxing Liao; Michael Hanus; Jason F Kelly; Craig W Stevens; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: Denise Bernhardt; Sebastian Adeberg; Farastuk Bozorgmehr; Nils Opfermann; Juliane Hörner-Rieber; Laila König; Jutta Kappes; Michael Thomas; Andreas Unterberg; Felix Herth; Claus Peter Heußel; Arne Warth; Jürgen Debus; Martin Steins; Stefan Rieken Journal: Strahlenther Onkol Date: 2017-10-30 Impact factor: 3.621
Authors: K Vekens; S Verbanck; C Collen; G Storme; K Barbé; M De Ridder; E Vanderhelst Journal: Strahlenther Onkol Date: 2019-07-12 Impact factor: 3.621
Authors: Mohammed Alharbi; Stefan Janssen; Heiko Golpon; Michael Bremer; Christoph Henkenberens Journal: Radiat Oncol Date: 2017-11-02 Impact factor: 3.481